517 related articles for article (PubMed ID: 28927416)
1. Tumor-related interleukins: old validated targets for new anti-cancer drug development.
Setrerrahmane S; Xu H
Mol Cancer; 2017 Sep; 16(1):153. PubMed ID: 28927416
[TBL] [Abstract][Full Text] [Related]
2. IL-35 induces N2 phenotype of neutrophils to promote tumor growth.
Zou JM; Qin J; Li YC; Wang Y; Li D; Shu Y; Luo C; Wang SS; Chi G; Guo F; Zhang GM; Feng ZH
Oncotarget; 2017 May; 8(20):33501-33514. PubMed ID: 28432279
[TBL] [Abstract][Full Text] [Related]
3. Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets.
Szebeni GJ; Vizler C; Nagy LI; Kitajka K; Puskas LG
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27886105
[TBL] [Abstract][Full Text] [Related]
4. Targeting interleukin-22 for cancer therapy.
Markota A; Endres S; Kobold S
Hum Vaccin Immunother; 2018; 14(8):2012-2015. PubMed ID: 29617184
[TBL] [Abstract][Full Text] [Related]
5. Heparanase: From basic research to therapeutic applications in cancer and inflammation.
Vlodavsky I; Singh P; Boyango I; Gutter-Kapon L; Elkin M; Sanderson RD; Ilan N
Drug Resist Updat; 2016 Nov; 29():54-75. PubMed ID: 27912844
[TBL] [Abstract][Full Text] [Related]
6. Epithelial-mesenchymal transition and inflammation at the site of the primary tumor.
Dominguez C; David JM; Palena C
Semin Cancer Biol; 2017 Dec; 47():177-184. PubMed ID: 28823497
[TBL] [Abstract][Full Text] [Related]
7. Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment.
Cui Y; Guo G
Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27869779
[TBL] [Abstract][Full Text] [Related]
8. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery.
Mosely SI; Prime JE; Sainson RC; Koopmann JO; Wang DY; Greenawalt DM; Ahdesmaki MJ; Leyland R; Mullins S; Pacelli L; Marcus D; Anderton J; Watkins A; Coates Ulrichsen J; Brohawn P; Higgs BW; McCourt M; Jones H; Harper JA; Morrow M; Valge-Archer V; Stewart R; Dovedi SJ; Wilkinson RW
Cancer Immunol Res; 2017 Jan; 5(1):29-41. PubMed ID: 27923825
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms and applications of interleukins in cancer immunotherapy.
Anestakis D; Petanidis S; Kalyvas S; Nday CM; Tsave O; Kioseoglou E; Salifoglou A
Int J Mol Sci; 2015 Jan; 16(1):1691-710. PubMed ID: 25590298
[TBL] [Abstract][Full Text] [Related]
10. Interleukin 32, inflammation and cancer.
Hong JT; Son DJ; Lee CK; Yoon DY; Lee DH; Park MH
Pharmacol Ther; 2017 Jun; 174():127-137. PubMed ID: 28223235
[TBL] [Abstract][Full Text] [Related]
11. Concise Review: Emerging Role of CD44 in Cancer Stem Cells: A Promising Biomarker and Therapeutic Target.
Yan Y; Zuo X; Wei D
Stem Cells Transl Med; 2015 Sep; 4(9):1033-43. PubMed ID: 26136504
[TBL] [Abstract][Full Text] [Related]
12. Reversing T-cell Dysfunction and Exhaustion in Cancer.
Zarour HM
Clin Cancer Res; 2016 Apr; 22(8):1856-64. PubMed ID: 27084739
[TBL] [Abstract][Full Text] [Related]
13. Decoding the Role of Interleukin-30 in the Crosstalk Between Cancer and Myeloid Cells.
Di Carlo E
Cells; 2020 Mar; 9(3):. PubMed ID: 32143355
[TBL] [Abstract][Full Text] [Related]
14. The JAK/STAT3 axis: A comprehensive drug target for solid malignancies.
Huynh J; Etemadi N; Hollande F; Ernst M; Buchert M
Semin Cancer Biol; 2017 Aug; 45():13-22. PubMed ID: 28647610
[TBL] [Abstract][Full Text] [Related]
15. Anti-CCR5 Therapy Circumvents Immune Cell Exploitation by Tumors.
Cancer Discov; 2016 Jun; 6(6):571. PubMed ID: 27125549
[TBL] [Abstract][Full Text] [Related]
16. IL-6 and related cytokines as the critical lynchpins between inflammation and cancer.
Taniguchi K; Karin M
Semin Immunol; 2014 Feb; 26(1):54-74. PubMed ID: 24552665
[TBL] [Abstract][Full Text] [Related]
17. IL-23 promotes tumour incidence and growth.
Langowski JL; Zhang X; Wu L; Mattson JD; Chen T; Smith K; Basham B; McClanahan T; Kastelein RA; Oft M
Nature; 2006 Jul; 442(7101):461-5. PubMed ID: 16688182
[TBL] [Abstract][Full Text] [Related]
18. Molecular Pathways: Targeting the CXCR4-CXCL12 Axis--Untapped Potential in the Tumor Microenvironment.
Scala S
Clin Cancer Res; 2015 Oct; 21(19):4278-85. PubMed ID: 26199389
[TBL] [Abstract][Full Text] [Related]
19. Role of the tumor microenvironment in regulating apoptosis and cancer progression.
Yaacoub K; Pedeux R; Tarte K; Guillaudeux T
Cancer Lett; 2016 Aug; 378(2):150-9. PubMed ID: 27224890
[TBL] [Abstract][Full Text] [Related]
20. The bad seed: Cancer stem cells in tumor development and resistance.
Koren E; Fuchs Y
Drug Resist Updat; 2016 Sep; 28():1-12. PubMed ID: 27620951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
